Now showing items 197-216 of 683

    • Divergent adaptation in thyroid cancers. 

      Sottoriva, A (2018-06)
    • DNA methylation-based classification of central nervous system tumours. 

      Capper, D; Jones, DTW; Sill, M; Hovestadt, V; Schrimpf, D; Sturm, D; Koelsche, C; Sahm, F; Chavez, L; Reuss, DE; Kratz, A; Wefers, AK; Huang, K; Pajtler, KW; Schweizer, L; Stichel, D; Olar, A; Engel, NW; Lindenberg, K; Harter, PN; Braczynski, AK; Plate, KH; Dohmen, H; Garvalov, BK; Coras, R; Hölsken, A; Hewer, E; Bewerunge-Hudler, M; Schick, M; Fischer, R; Beschorner, R; Schittenhelm, J; Staszewski, O; Wani, K; Varlet, P; Pages, M; Temming, P; Lohmann, D; Selt, F; Witt, H; Milde, T; Witt, O; Aronica, E; Giangaspero, F; Rushing, E; Scheurlen, W; Geisenberger, C; Rodriguez, FJ; Becker, A; Preusser, M; Haberler, C; Bjerkvig, R; Cryan, J; Farrell, M; Deckert, M; Hench, J; Frank, S; Serrano, J; Kannan, K; Tsirigos, A; Brück, W; Hofer, S; Brehmer, S; Seiz-Rosenhagen, M; Hänggi, D; Hans, V; Rozsnoki, S; Hansford, JR; Kohlhof, P; Kristensen, BW; Lechner, M; Lopes, B; Mawrin, C; Ketter, R; Kulozik, A; Khatib, Z; Heppner, F; Koch, A; Jouvet, A; Keohane, C; Mühleisen, H; Mueller, W; Pohl, U; Prinz, M; Benner, A; Zapatka, M; Gottardo, NG; Driever, PH; Kramm, CM; Müller, HL; Rutkowski, S; von Hoff, K; Frühwald, MC; Gnekow, A; Fleischhack, G; Tippelt, S; Calaminus, G; Monoranu, C-M; Perry, A; Jones, C; Jacques, TS; Radlwimmer, B; Gessi, M; Pietsch, T; Schramm, J; Schackert, G; Westphal, M; Reifenberger, G; Wesseling, P; Weller, M; Collins, VP; Blümcke, I; Bendszus, M; Debus, J; Huang, A; Jabado, N; Northcott, PA; Paulus, W; Gajjar, A; Robinson, GW; Taylor, MD; Jaunmuktane, Z; Ryzhova, M; Platten, M; Unterberg, A; Wick, W; Karajannis, MA; Mittelbronn, M; Acker, T; Hartmann, C; Aldape, K; Schüller, U; Buslei, R; Lichter, P; Kool, M; Herold-Mende, C; Ellison, DW; Hasselblatt, M; Snuderl, M; Brandner, S; Korshunov, A; von Deimling, A; Pfister, SM (2018-03-14)
      Accurate pathological diagnosis is crucial for optimal management of patients with cancer. For the approximately 100 known tumour types of the central nervous system, standardization of the diagnostic process has been shown ...
    • DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. 

      Touat, M; Sourisseau, T; Dorvault, N; Chabanon, RM; Garrido, M; Morel, D; Krastev, DB; Bigot, L; Adam, J; Frankum, JR; Durand, S; Pontoizeau, C; Souquère, S; Kuo, M-S; Sauvaigo, S; Mardakheh, F; Sarasin, A; Olaussen, KA; Friboulet, L; Bouillaud, F; Pierron, G; Ashworth, A; Lombès, A; Lord, CJ; Soria, J-C; Postel-Vinay, S (2018-04)
      Synthetic lethality is an efficient mechanism-based approach to selectively target DNA repair defects. Excision repair cross-complementation group 1 (ERCC1) deficiency is frequently found in non-small-cell lung cancer ...
    • DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. 

      Mateo, J; Carreira, S; Sandhu, S; Miranda, S; Mossop, H; Perez-Lopez, R; Nava Rodrigues, D; Robinson, D; Omlin, A; Tunariu, N; Boysen, G; Porta, N; Flohr, P; Gillman, A; Figueiredo, I; Paulding, C; Seed, G; Jain, S; Ralph, C; Protheroe, A; Hussain, S; Jones, R; Elliott, T; McGovern, U; Bianchini, D; Goodall, J; Zafeiriou, Z; Williamson, CT; Ferraldeschi, R; Riisnaes, R; Ebbs, B; Fowler, G; Roda, D; Yuan, W; Wu, YM; Cao, X; Brough, R; Pemberton, H; A'Hern, R; Swain, A; Kunju, LP; Eeles, R; Attard, G; Lord, CJ; Ashworth, A; Rubin, MA; Knudsen, KE; Feng, FY; Chinnaiyan, AM; Hall, E; de Bono, JS
      Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to ...
    • Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer. 

      Natrajan, R; Tutt, ANJ; Lord, CJ (2018-03)
      <b/> Two reports in this issue of Cancer Discovery outline how the genomic composition of tumors, including the presence of intragenic gene fusions, could inform the selection of treatment approaches in aggressive forms ...
    • Drug repositioning in sarcomas and other rare tumors. 

      Lee, ATJ; Huang, PH; Pollack, SM; Jones, RL (2016-04)
    • Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors. 

      Wong, JP; Todd, JR; Finetti, MA; McCarthy, F; Broncel, M; Vyse, S; Luczynski, MT; Crosier, S; Ryall, KA; Holmes, K; Payne, LS; Daley, F; Wai, P; Jenks, A; Tanos, B; Tan, A-C; Natrajan, RC; Williamson, D; Huang, PH (2016-10)
      Subunits of the SWI/SNF chromatin remodeling complex are mutated in a significant proportion of human cancers. Malignant rhabdoid tumors (MRTs) are lethal pediatric cancers characterized by a deficiency in the SWI/SNF ...
    • Dysregulation of Alternative Poly-adenylation as a Potential Player in Autism Spectrum Disorder. 

      Szkop, KJ; Cooke, PIC; Humphries, JA; Kalna, V; Moss, DS; Schuster, EF; Nobeli, I (2017-01)
      We present here the hypothesis that alternative poly-adenylation (APA) is dysregulated in the brains of individuals affected by Autism Spectrum Disorder (ASD), due to disruptions in the calcium signaling networks. APA, the ...
    • E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. 

      Bajrami, I; Marlow, R; van de Ven, M; Brough, R; Pemberton, HN; Frankum, J; Song, F; Rafiq, R; Konde, A; Krastev, DB; Menon, M; Campbell, J; Gulati, A; Kumar, R; Pettitt, SJ; Gurden, MD; Cardenosa, ML; Chong, I; Gazinska, P; Wallberg, F; Sawyer, EJ; Martin, L-A; Dowsett, M; Linardopoulos, S; Natrajan, R; Ryan, CJ; Derksen, PWB; Jonkers, J; Tutt, ANJ; Ashworth, A; Lord, CJ (2018-04)
      The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumors. Precision medicine approaches that exploit this characteristic are not available. Using perturbation screens in breast tumor cells ...
    • Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer (vol 76, pg 2301, 2016) 

      Herrera-Abreu, MT; Palafox, M; Asghar, U; Rivas, MA; Cutts, RJ; Garcia-Murillas, I; Pearson, A; Guzman, M; Rodriguez, O; Grueso, J; Bellet, M; Cortes, J; Elliott, R; Pancholi, S; Lord, CJ; Baselga, J; Dowsett, M; Martin, L-A; Turner, NC; Serra, V (2016-10)
    • Early enrichment of ESR1 mutations and the impact on gene expression in pre-surgical primary breast cancer treated with aromatase inhibitors. 

      Leal, MF; Haynes, BP; Schuster, EF; Yeo, B; Afentakis, M; Zabaglo, L; Martins, V; Buus, R; Dodson, A; Cheang, MCU; Smith, IE; Martin, L-A; Dowsett, M (2019-09-23)
      PURPOSE: To investigate the presence of ESR1 mutation in primary oestrogen-receptor positive breast cancer (ER+BC) treated with extended (>4 weeks) neoadjuvant (pre-surgical) aromatase inhibitor (NAI) therapy and to identify ...
    • Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors. 

      Leal, MF; Haynes, BP; Schuster, E; Yeo, B; Afentakis, M; Zabaglo, L; Martins, V; Buus, R; Dodson, A; Cheang, MCU; Smith, IE; Martin, L-A; Dowsett, M (2019-12)
      PURPOSE:To investigate the presence of ESR1 mutations in primary estrogen-receptor-positive (ER+) breast cancer treated with extended (>4 weeks) neoadjuvant (presurgical) aromatase inhibitor (NAI) therapy and to identify ...
    • Early enrichment of ESR1 mutations and the impact on gene expression in primary breast cancer treated with aromatase inhibitors in the pre-surgical setting 

      Dowsett, M; Ferreira Leal, M; Haynes, B; Schuster, E; Yeo, B; Afentakis, M; Zabaglo, L; Martins, V; Buus, R; Dodson, A; Cheang, M; Smith, I; Martin, L-A
    • Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. 

      Smyth, EC; Fassan, M; Cunningham, D; Allum, WH; Okines, AFC; Lampis, A; Hahne, JC; Rugge, M; Peckitt, C; Nankivell, M; Langley, R; Ghidini, M; Braconi, C; Wotherspoon, A; Grabsch, HI; Valeri, N (2016-08)
      PURPOSE:The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial established perioperative epirubicin, cisplatin, and fluorouracil chemotherapy as a standard of care for patients with resectable ...
    • Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. 

      Khan, K; Rane, JK; Cunningham, D; Rao, S; Watkins, D; Starling, N; Kalaitzaki, E; Forster, M; Braconi, C; Valeri, N; Gerlinger, M; Chau, I (2019-03)
      BACKGROUND:Gastrointestinal (GI) cancer patients may not be considered for therapy with fluoropyrimidines (FPs) because of previous cardiovascular (CV) toxicity or preexisting risk factors; such patients may benefit from ...
    • The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience. 

      Sriskandarajah, P; Pawlyn, C; Mohammed, K; Dearden, CE; Davies, FE; Morgan, GJ; Boyd, KD; Kaiser, MF (2017-02)
    • Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. 

      Pender, A; Garcia-Murillas, I; Rana, S; Cutts, RJ; Kelly, G; Fenwick, K; Kozarewa, I; Gonzalez de Castro, D; Bhosle, J; O'Brien, M; Turner, NC; Popat, S; Downward, J (2015-01)
      Droplet digital PCR (ddPCR) can be used to detect low frequency mutations in oncogene-driven lung cancer. The range of KRAS point mutations observed in NSCLC necessitates a multiplex approach to efficient mutation detection ...
    • Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. 

      Nikkilä, J; Kumar, R; Campbell, J; Brandsma, I; Pemberton, HN; Wallberg, F; Nagy, K; Scheer, I; Vertessy, BG; Serebrenik, AA; Monni, V; Harris, RS; Pettitt, SJ; Ashworth, A; Lord, CJ (2017-06)
      Elevated APOBEC3B expression in tumours correlates with a kataegic pattern of localised hypermutation. We assessed the cellular phenotypes associated with high-level APOBEC3B expression and the influence of p53 status on ...
    • Elevated Platelet Count Appears to Be Causally Associated with Increased Risk of Lung Cancer: A Mendelian Randomization Analysis. 

      Zhu, Y; Wei, Y; Zhang, R; Dong, X; Shen, S; Zhao, Y; Bai, J; Albanes, D; Caporaso, NE; Landi, MT; Zhu, B; Chanock, SJ; Gu, F; Lam, S; Tsao, M-S; Shepherd, FA; Tardon, A; Fernández-Somoano, A; Fernandez-Tardon, G; Chen, C; Barnett, MJ; Doherty, J; Bojesen, SE; Johansson, M; Brennan, P; McKay, JD; Carreras-Torres, R; Muley, T; Risch, A; Wichmann, H-E; Bickeboeller, H; Rosenberger, A; Rennert, G; Saliba, W; Arnold, SM; Field, JK; Davies, MPA; Marcus, MW; Wu, X; Ye, Y; Le Marchand, L; Wilkens, LR; Melander, O; Manjer, J; Brunnström, H; Hung, RJ; Liu, G; Brhane, Y; Kachuri, L; Andrew, AS; Duell, EJ; Kiemeney, LA; van der Heijden, EH; Haugen, A; Zienolddiny, S; Skaug, V; Grankvist, K; Johansson, M; Woll, PJ; Cox, A; Taylor, F; Teare, DM; Lazarus, P; Schabath, MB; Aldrich, MC; Houlston, RS; McLaughlin, J; Stevens, VL; Shen, H; Hu, Z; Dai, J; Amos, CI; Han, Y; Zhu, D; Goodman, GE; Chen, F; Christiani, DC (2019-05)
      BACKGROUND:Platelets are a critical element in coagulation and inflammation, and activated platelets are linked to cancer risk through diverse mechanisms. However, a causal relationship between platelets and risk of lung ...
    • Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. 

      Jeselsohn, R; Cornwell, M; Pun, M; Buchwalter, G; Nguyen, M; Bango, C; Huang, Y; Kuang, Y; Paweletz, C; Fu, X; Nardone, A; De Angelis, C; Detre, S; Dodson, A; Mohammed, H; Carroll, JS; Bowden, M; Rao, P; Long, HW; Li, F; Dowsett, M; Schiff, R; Brown, M (2017-05-15)
      The estrogen receptor (ER) drives the growth of most luminal breast cancers and is the primary target of endocrine therapy. Although ER blockade with drugs such as tamoxifen is very effective, a major clinical limitation ...